When did the FDA approve SkinVive?

The date is the easy part of this question. The mistake it invites is treating approval as a green light for any use on any face.

The date, and where it comes from

The announcement at news.abbvie.com carries its date in the headline: SKINVIVE™ by JUVÉDERM® Receives U.S. FDA Approval - May 15, 2023. That puts the announcement on May 15, 2023.

What was approved, and for whom

www.dermatologytimes.com reports the scope in one sentence: the FDA "has approved Skinvive by Juvederm, the first hyaluronic acid intradermal microdroplet injection, for improving skin smoothness in adult patients ages 21 and older."

The scope is narrow. It names one goal, improving skin smoothness, and one group, adults ages 21 and older.

Popular coverage frames it more loosely. An article calling SkinVive an injectable that doubles as skincare shows how it is pitched, but the approval wording is the boundary, not the pitch.

Approval is not a fit check

Do not decide for yourself that an approval makes the treatment right for you. Approval describes a product and its stated use, and it says nothing about your skin.

A trained injector who has examined you is the person to make that call. If you are comparing providers around Mt Olive, ask each one what the approved use is and how your plan fits inside it.

When "approved" ends the conversation

An approval date answers when, not whether. If a provider uses the word "approved" to end the conversation, ask what exactly was approved and for whom.